William Blair analyst Andrew Brackmann downgraded Exact Sciences (EXAS) to Market Perform from Outperform after the company announced an agreement to be acquired by Abbott (ABT) for $105 per share. The firm believes the strategic and financial rationale for the acquisition “makes sense for Abbott,” the analyst tells investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Exact Sciences downgraded to Peer Perform from Outperform at Wolfe Research
- Exact Sciences downgraded to Neutral from Buy at BTIG
- Exact Sciences downgraded to Neutral from Buy at Citi
- Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
- Exact Sciences downgraded to Market Perform from Outperform at Leerink